Cingulate Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 6.93 million compared to USD 4.61 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.701 USD | -2.26% | -11.12% | -90.84% |
May. 21 | FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD | CI |
May. 08 | Cingulate Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-90.84% | 4.56M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- CING Stock
- News Cingulate Inc.
- Cingulate Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023